Medical Marijuana and Its Effects on Motor Function in People With Multiple Sclerosis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02898974 |
Recruitment Status :
Completed
First Posted : September 13, 2016
Results First Posted : February 5, 2020
Last Update Posted : February 5, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Multiple Sclerosis | Behavioral: Medical Marijuana |
Study Type : | Observational |
Actual Enrollment : | 22 participants |
Observational Model: | Case-Only |
Time Perspective: | Prospective |
Official Title: | Medical Marijuana and Its Effects on Motor Function in People With Multiple Sclerosis: An Observational Case-control Study |
Study Start Date : | September 2016 |
Actual Primary Completion Date : | October 2017 |
Actual Study Completion Date : | October 2017 |

Group/Cohort | Intervention/treatment |
---|---|
Regular Medical Marijuana users
People with MS that are regular Medical Marijuana users
|
Behavioral: Medical Marijuana
To investigate the effects of medical marijuana usage on physical function we will employ an observational case-control design |
Non Users of Medical Marijuana
People with MS that are non users of Medical Marijuana
|
- Fatigue [ Time Frame: Through study completion, an average of 6 months. ]Strength decline during fatiguing muscle contraction measured with force transducer
- Muscle Strength [ Time Frame: Through study completion, an average of 6 months. ]Maximal muscle strength measured with force transducer
- Postural Stability [ Time Frame: Through study completion, an average of 6 months. ]Timed up and go

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 30 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Medically diagnosed with MS,
- 30-60 years of age,
- Moderate disability (Patient Determined Disease Steps score 2-6).
Exclusion Criteria:
- Relapse with the last 60 days,
- High risk for cardiovascular disease (American College of Sports Medicine risk classification),
- Changes in disease modifying medications within the last 45 days,
- Concurrent neurological/neuromuscular disease,
- Hospitalization within the last 90 days,
- Inability to understand/sign informed consent.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02898974
United States, Colorado | |
Department of Health and Exercise Science | |
Fort Collins, Colorado, United States, 80523 |
Principal Investigator: | Thorsten Rudroff, Ph.D. | Colorado State University |
Documents provided by Thorsten Rudroff, Colorado State University:
Responsible Party: | Thorsten Rudroff, Assistant Professor, Colorado State University |
ClinicalTrials.gov Identifier: | NCT02898974 |
Other Study ID Numbers: |
16-6685HH |
First Posted: | September 13, 2016 Key Record Dates |
Results First Posted: | February 5, 2020 |
Last Update Posted: | February 5, 2020 |
Last Verified: | February 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Multiple Sclerosis Sclerosis Pathologic Processes Demyelinating Autoimmune Diseases, CNS Autoimmune Diseases of the Nervous System |
Nervous System Diseases Demyelinating Diseases Autoimmune Diseases Immune System Diseases |